Clinical Trial Update: Expansion of Invariant NKT Cells for a Cell Immunotherapeutic Approach Allowing the Control of Graft Versus Host-disease and Preserving the Graft Versus Leukemia Effect After Allogeneic Hematopoietic Stem Cell Transplantation

View source ↗

Summary

This clinical trial update describes expanding invariant natural killer T (iNKT) cells as a cell therapy to control graft-versus-host disease and preserve the g…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Invariant NKT cell product (Invariant natural killer T (iNKT) cell)

Snippet

Sponsor: Central Hospital, Nancy, France | Conditions: Allogeneic Hematopoietic Stem Cell (HSC) Transplantation | Status: UNKNOWN